Serina Therapeutics, based in Alameda, California, is a clinical-stage biotechnology company developing drug candidates for neurological diseases, focusing on SER-252 for Parkinson's Disease. The company went public on November 29, 2018, and employs four people.
Randall Moreadith sold 5,500 shares of SER on 4 August at $5.17 per share, worth a total of $28K. They now own 0 SER shares, or a 100% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
